Skip to content

PHARBIOMED

Active
Private limited companyfounded 2015active for 11 yearsReper-Vrevenstraat 16, 1020 Brussel, BelgiumKBO/BCE: BE 0597.824.559
Summary

PHARBIOMED has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €235,802 and a net result of €258,313. Equity remains stable across the filed financial years (±0.3% per year). Its solvency ranks better than 76% of 22,632 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).

Risk analysisFollow ReportCompare
PHARBIOMEDActiveChecked score 90/100
Risk analysis ReportCompare

Overview

Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
≈ €1.6mturnover 2025, estimated
Staff
2.4 FTE
Equity
€235,802
Profit
€258,313
Turnover estimated from the gross margin
Financial health
90 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.3%
Structure
2025 accounts filed 31 days late1 of 3 deeds summarised
Why 90raises riskLast filed accounts filed 31 days late; 2 of the last 3 latelowers riskLiquidity: current ratio 1.31, cash €102,546Founded in 2015Equity €235,802 (63.8% of total assets)Show the evidence

Checked score

Score 2025
90 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 86% of its sector peers (NACE 47, micro)
Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Strong
Solvency 89+48
equity 63.8% of total assets
Liquidity 68+22
short-term debt 36.2% · cash 27.7%
Profitability 100=
return on assets 69.8%
Bankruptcy probability, 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%

About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,263 companies, NACE 47, micro)
Last 24 months 11-2024: 0.7% 12-2024: 0.7%● unchanged vs 11-2024 01-2025: 0.6%▼ -0.1 percentage points vs 12-2024 02-2025: 0.6%● unchanged vs 01-2025 03-2025: 0.6%● unchanged vs 02-2025 04-2025: 0.7%▲ +0.1 percentage points vs 03-2025 05-2025: 0.7%● unchanged vs 04-2025 06-2025: 0.7%● unchanged vs 05-2025 07-2025: 0.8%▲ +0.1 percentage points vs 06-2025 08-2025: 1.1%▲ +0.3 percentage points vs 07-2025 09-2025: 1.4%▲ +0.3 percentage points vs 08-2025highest value 10-2025: 0.8%▼ -0.6 percentage points vs 09-2025 11-2025: 0.8%● unchanged vs 10-2025 12-2025: 0.8%● unchanged vs 11-2025 01-2026: 0.8%● unchanged vs 12-2025 02-2026: 0.8%● unchanged vs 01-2026 03-2026: 0.7%▼ -0.1 percentage points vs 02-2026 04-2026: 0.7%● unchanged vs 03-2026 05-2026: 0.7%● unchanged vs 04-2026 06-2026: 0.6%▼ -0.1 percentage points vs 05-2026 07-2026: 0.7%▲ +0.1 percentage points vs 06-2026 08-2026: 1.1%▲ +0.4 percentage points vs 07-2026 09-2026: 0.4%▼ -0.7 percentage points vs 08-2026 10-2026: 0.3%▼ -0.1 percentage points vs 09-2026lowest value
Credit of up to €21,000 on 30-day terms is acceptable
Liquidity tight (current ratio 1.31, compared with 1.17 in 2024, below the usual 1.5; short-term debt: 36.2% and cash: 27.7% of total assets), and 36.2% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 76% on solvency, 75% on liquidity, 96% on profitability and 99% on growth.

The bankruptcy probability was computed on 29-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
lowers riskraises risk
raises risk · Last filed accounts filed 31 days late; 2 of the last 3 late
NBB · filings
lowers risk · Liquidity: current ratio 1.31, cash €102,546
NBB · annual accounts
lowers risk · Founded in 2015
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
lowers risk · Equity €235,802 (63.8% of total assets)
NBB · annual accounts
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025
Equity per financial year
1819202122232425
2018 to 2025 · latest year €235,802
raises risk · 2025 accounts filed 31 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filings
Deviation from the deadline
2025
31 days late
2024
31 days late
2023
28 days late
2022
44 days early
2021
41 days early
2020
33 days early
2019
37 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 9 days before the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 August (4 of the last 5 filed years within 70 days of that day).
Companies Code · seven months
Where today falls in the filing period
29-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · micro…
  2. Highest result from 2018 to 2025net €258,313 ▲263%
  3. Equity above €200,000equity €235,802 ▲758%

Key points

  • Positive: Result rose in 2025from €71,213 to €258,313 ▲ 263% View
  • Positive: Among the best 5% on net resultsector median €5,089 · 22,613 companies €258,313 View
  • Positive: 8 profitable years in a rowprofit 2025: €258,313 8 years View

By topic

Financials

Financial year
2025
Total assets
€369,863
Profit
€258,313
Solvency
63.8%
Total assets▲ 117%
Net result
20182025
Go to Financials

Timeline

Events
14
Since
2017
Next accounts
by 31-07-2027
  1. 31-08-2025Annual accounts filed
  2. 28-08-2024Annual accounts filed
  3. 26-02-2024Appointments: EL KENZ Hanane (director) and EL…
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Retail sale of pharmaceutical productsNACE 47730
Founded
10-02-2015
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Key facts about PHARBIOMED

What is the company number of PHARBIOMED?
0597.824.559. In Belgium the VAT number is the company number with BE in front: BE 0597.824.559.
Where is PHARBIOMED based?
The registered office is at Reper-Vrevenstraat 16, 1020 Brussel.Company details
What does PHARBIOMED do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of PHARBIOMED?
Private limited company (BV).
When was PHARBIOMED founded?
On 10-02-2015.
Is PHARBIOMED still active?
Yes, PHARBIOMED is an active enterprise in the KBO register.
How many employees does PHARBIOMED have?
On average 2.4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of PHARBIOMED?
Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
Is PHARBIOMED profitable?
In financial year 2025, PHARBIOMED made a profit of €258,313.
Where can I find the annual accounts of PHARBIOMED?
PHARBIOMED filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of PHARBIOMED due?
By 31-07-2027, for financial year 2026.Timeline

Companies related to PHARBIOMED

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure